Alzheimer's Disease

A new study reveals that the 3D organization of DNA is disrupted in brain cells affected by Alzheimer's disease, altering gene activity.

Vanderbilt researchers developed two new compounds to study the TAOK protein family, linked to Alzheimer's disease, potentially revealing new disease mechanisms and treatment strategies.

Scientists have identified a biological tipping point in microglial behavior that may determine whether Alzheimer's pathology leads to dementia, offering new treatment targets.

A new study reveals that cancer-linked mutations found in immune cells may contribute to Alzheimer's disease, suggesting new diagnostic and treatment avenues.

Scientists at ETH Zurich identified a new Alzheimer's trigger and developed an experimental compound that slowed nerve cell loss and extended lifespan in mice.

Scientists have discovered a molecular switch involving the STING protein that drives brain inflammation in Alzheimer's disease, offering a new target for treatments.

Scientists have identified the enzyme IDOL as a potential new target for Alzheimer's treatment, finding that its removal from neurons significantly reduced amyloid plaques and improved brain resilience in lab studies.

A new study reveals that the amino acid arginine can significantly reduce toxic amyloid protein buildup and inflammation in animal models of Alzheimer's disease.

Researchers discovered that boosting a protein called Sox9 helps the brain's astrocytes clear Alzheimer's plaques and preserve cognitive function in mice.

Researchers have studied SuperAgers, individuals over 80 with memory like 50-year-olds, finding unique brain structures and social traits that resist or adapt to Alzheimer's-related changes.

A routine blood test marker, the neutrophil to lymphocyte ratio, may predict a person's risk of developing Alzheimer's disease years before symptoms appear, suggesting immune cells could play a role in the disease's progression.